We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesOcean Biomedical Inc.

Ocean Biomedical Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
7780
Market Cap
0.23M

Momentum Score

…

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases in the United States. The company's oncology product candidates include OCX-253 anti-Chi3l1 Single-target mAb and OCX-410 anti-Chi3l1/PD-1 Bi-specific antibody for the treatment of non-small cell lung cancer; and OCX-909 anti-Chi3l1/CTLA-4 Bi-specific antibody to treat glioblastoma multiforme. Its fibrosis product candidates consist of OCF-203 anti-Chit1 small molecule for the treatment of idiopathic pulmonary fibrosis (IPF) and hermansky-pudlak syndrome (HPS). The company's infectious diseases product candidates for malaria include the ODA-570 vaccine for the prevention of P. falciparum infection; ODA-611 anti-PfGARP mAb for the treatment of Symptomatic P. falciparum infection; and ODA-579 anti-PfGARP small molecule for the treatment of Symptomatic P. falciparum infection. It has license agreement with Elkurt, Inc. for FRG Antibody, bi-specific antibody anti-CTLA4, bispecific (FRG)x anti-PD-1 (FRGxPD-1), chit1 small molecule antifibrotic, and malaria small molecules and antibodies. The company was founded in 2019 and is based in Providence, Rhode Island. Ocean Biomedical, Inc. is a subsidiary of Poseidon Bio, LLC.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
-
Low
0.01
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public disclosures on Ocean Biomedical Inc., an OTC Pink-listed company, are sparse and provide little detail on operations or any development programs. The company appears to be a small biopharmaceutical developer whose long-term growth would depend on clinical progress, regulatory approvals, and partnership or financing events, which may benefit investors seeking early-stage biotech exposure.
Material risks include low liquidity, typical early-stage biotech uncertainties such as clinical and regulatory failure, and high financing and dilution risk associated with Pink-listed issuers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.17
ROE
-
Net Debt
16.30M
ROCE
11.51%
Diluted EPS TTM
-9.10

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -3.30M -114.47M -0.96M -62.34M -1.65M
Net income -3.30M -114.47M 0.57M -62.34M -1.65M
Selling general administrative 3.77M 9.51M - 28.41M 1.60M
Ebit - - -2.48M -62.34M -1.65M
Ebitda -7.43M - -0.96M -62.34M -1.65M
Depreciation and amortization - - 1.52M - -0.00M
Operating income -3.80M -10.21M -2.48M -62.34M -1.65M
Other operating expenses 3.80M - 2.48M 62.34M 1.65M
Interest expense 2.05M 1.76M 0.00M 0.00M -
Interest income - - 1.52M - -
Net interest income -2.05M -1.76M 1.52M - -
Income tax expense - - -1.52M -0.00M 0.00M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 3.80M 10.21M 2.48M 62.34M 1.65M
Total other income expense net -5.68M -102.49M 1.52M 0.00M -0.00M
Net income from continuing ops -9.48M -114.47M -0.96M -62.34M -1.65M
Net income applicable to common shares - - - -62.34M -1.65M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 0.90M 5.50M 110.91M 0.08M 0.39M
Other current assets 0.81M 2.10M - 0.47M 0.39M
Total liab 98.52M 96.26M 6.61M 6.74M 2.27M
Total stockholder equity -97.62M -90.76M 104.30M -6.66M -1.89M
Other current liab 16.79M 16.96M 0.99M 6.50M 2.22M
Common stock - - 110.44M 107.10M -
Capital stock 0.00M 0.00M 110.44M 0.00M -
Retained earnings -205.53M -196.06M -2.77M -64.23M -1.89M
Other assets - - - -107.10M -
Cash 0.22M 0.00M 0.33M 0.06M -
Total current liabilities 33.89M 30.01M 3.46M 6.74M 2.27M
Net debt 16.30M 12.11M 1.82M -0.06M -
Short term debt 16.30M 12.12M 2.15M - -
Short long term debt 16.30M 12.12M 2.15M - -
Short long term debt total 16.30M 12.12M 2.15M - -
Other stockholder equity 107.92M 105.29M -3.38M 57.57M -
Total current assets 0.81M 2.11M 0.47M 0.08M 0.39M
Long term investments 0.09M 3.39M - - -
Net tangible assets - - - -6.66M -1.89M
Net receivables - - 0.05M - -
Accounts payable 0.80M 0.93M 0.32M 0.24M 0.05M
Non currrent assets other 0.09M - 110.44M 107.10M -
Non current assets total 0.09M 3.39M 110.44M 107.10M 0.00M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments - - -2.10M 0.00M 0.00M
Change to liabilities - - - 0.00M 0.00M
Net borrowings 3.40M 6.81M - - -
Total cash from financing activities 3.40M 10.40M 2.10M 1.11M 0.06M
Change to operating activities - - - 4.74M 1.59M
Net income -9.48M -114.47M -0.96M -62.34M -1.65M
Change in cash -0.78M 0.97M -0.75M 0.06M 0.06M
Begin period cash flow 1.00M 0.03M 1.08M 107.10M 0.00M
End period cash flow 0.22M 1.00M 0.33M 0.06M 107.10M
Total cash from operating activities -4.18M -9.43M -0.75M -1.05M -0.06M
Issuance of capital stock 0.00M 15.77M 0.00M 1.02M -
Sale purchase of stock 0.00M -64.28M - - -
Other cashflows from financing activities 3.40M 52.10M -2.10M 0.10M 0.06M
Change to netincome - - - 56.55M 56.55M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 1.04M 1.18M 1.74M 4.74M 1.59M
Stock based compensation 0.74M 1.21M - 56.55M -
Other non cash items 3.51M 102.65M -1.52M - -
Free cash flow -4.18M -9.43M -0.75M -1.05M -0.06M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
OCEA
Ocean Biomedical Inc.		 -
-%		 0.00 - - - 100.67 -9.48
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Ocean Biomedical Inc.

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases in the United States. The company's oncology product candidates include OCX-253 anti-Chi3l1 Single-target mAb and OCX-410 anti-Chi3l1/PD-1 Bi-specific antibody for the treatment of non-small cell lung cancer; and OCX-909 anti-Chi3l1/CTLA-4 Bi-specific antibody to treat glioblastoma multiforme. Its fibrosis product candidates consist of OCF-203 anti-Chit1 small molecule for the treatment of idiopathic pulmonary fibrosis (IPF) and hermansky-pudlak syndrome (HPS). The company's infectious diseases product candidates for malaria include the ODA-570 vaccine for the prevention of P. falciparum infection; ODA-611 anti-PfGARP mAb for the treatment of Symptomatic P. falciparum infection; and ODA-579 anti-PfGARP small molecule for the treatment of Symptomatic P. falciparum infection. It has license agreement with Elkurt, Inc. for FRG Antibody, bi-specific antibody anti-CTLA4, bispecific (FRG)x anti-PD-1 (FRGxPD-1), chit1 small molecule antifibrotic, and malaria small molecules and antibodies. The company was founded in 2019 and is based in Providence, Rhode Island. Ocean Biomedical, Inc. is a subsidiary of Poseidon Bio, LLC.

55 Claverick Street, Providence, RI, United States, 02903

401 444 7375

https://www.oceanbiomedical.com

7

Name Title Year Born
Ms. Elizabeth Ng M.B.A. CEO & Director 1957
Dr. Inderjote Kathuria M.B.A., M.D. Chief Strategy Officer 1967
Dr. Chirinjeev Baboo Kathuria M.B.A., M.D. Founder & Executive Chairman of the Board 1965
Dr. Jack A. Elias M.D. Founder, Chairman of Scientific Advisory Board & Independent Director 1951
Dr. Jonathan Kurtis M.D., Ph.D. Founder, Chairman of Scientific Advisory Board & Director 1969
Ms. Jolie G. Kahn CPA, Esq. Chief Financial Officer 1965
Mr. Robert John Sweeney Chief Accounting Officer & Assistant Secretary 1965
Dr. Inderjote Kathuria M.B.A., M.D. Chief Strategy Officer 1968
Dr. Chirinjeev Baboo Kathuria M.B.A., M.D. Founder & Executive Chairman of the Board 1966
Ms. Jolie G. Kahn C.P.A., Esq. Chief Financial Officer 1965

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…